Clinical Trial

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.
Protocol Amendment History 2 changes
notable Trial sites expanded: 80 -> 83 locations 2026-04-23
notable Trial sites reduced: 83 -> 80 locations 2026-04-17
Trial Details
NCT Number NCT04973605
Lead Sponsor BeOne Medicines
Conditions Relapsed/Refractory Multiple Myeloma
Enrollment 246 participants
Start Date 2021-09-16
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-07